Artivion

AORT

Market cap $1.83B

AORT jumps after FDA approves NEXUS Aortic Arch System, unlocking a potential Endospan acquisition and advancing minimally invasive care for high-risk patients.

Artivion (AORT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Endospan's NEXUS branched endovascular stent graft system shown to effectively treat aortic arch disease, including chronic aortic dissections ATLANTA, April 7, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the NEXUS® Aortic Arch System, developed by Endospan Ltd. ("Endospan"), Artivion's long-standing partner.

ATLANTA, March 3, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate virtually at the upcoming Oppenheimer 36th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 9:20 a.m.

Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript

Artivion (AORT) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to break-even earnings per share a year ago.

Fourth Quarter Highlights: GAAP revenue was $116.0 million in the fourth quarter of 2025 versus $97.3 million in the fourth quarter of 2024. For the full year, GAAP revenue was $441.3 million versus $388.5 million for the full year of 2024.

1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low Morbidity 2-Year Data from the AMDS PERSEVERE IDE Trial Further Demonstrate the Persistent Clinical Benefit of AMDS ATLANTA, Feb. 2, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE IDE trial and its AMDS PERSEVERE IDE trial at the 62nd Annual Meeting of the Society of Thoracic Surgeons in New Orleans, Louisiana.   The NEXUS TRIOMPHE IDE trial presentation of 94 patients highlighted 94% patient survival from lesion related death and 91% freedom from disabling stroke at 1-year post-treatment in this high-risk patient group.

ATLANTA, Jan. 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter 2025 financial results will be released on Thursday, February 12, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

Artivion continues to outperform the med-tech sector, driven by strong execution in stent grafts and On-X valve businesses. Recent clinical updates for the AMDS prosthesis reinforce its safety and efficacy, supporting further adoption and de-risking full commercialization. I expect double-digit long-term revenue growth, expanding EBITDA margins, and a fair value in the high-$50s, justifying a bullish stance.